Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3739490 | 1.00 | HTR2A (0.36) | HTR2AHTR1AHTR2CHTR2BMEN1 | |
| SCHEMBL1474652 | 1.00 | HTR2A (0.36) | HTR2AHTR1AHTR2CHTR2BMEN1 | |
| SCHEMBL6271247 | 0.99 | HTR2A (0.35) | HTR2AHTR1AHTR2CHTR2BMEN1 | |
| Tetrazole SCHEMBL5145009 | 0.90 | HTR2A (0.31) | HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL6271251 | 0.88 | MEN1 (0.31) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL29082484 | 0.88 | HTR2A (0.34) | HTR2AHTR1AHTR2CHTR2BMEN1 | |
| SCHEMBL23488 | 0.88 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2BALDH1A1 | |
| SCHEMBL29356973 | 0.88 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2BALDH1A1 | |
| Phosphoric Acid SCHEMBL8156858 | 0.86 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2BALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL20492883 | 0.86 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117890357-B | Single-component color development liquid and preparation method and detection method thereof | 深圳爱信生物技术有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-117890357-A | Single-component color development liquid and preparation method and detection method thereof | 深圳爱信生物技术有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-7667007-B2 | αvβ3-specific antibodies | APPLIED MOLECULAR EVOLUTION, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090023900-A1 | Anti-AlphaVBeta3 Recombinant Human Antibodies, Nucleic Acids Encoding Same | APPLIED MOLECULAR EVOLUTION, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-7422745-B2 | Methods of treating cancer with vαβ3-specific antibodies | APPLIED MOLECULAR EVOLUTION, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7371382-B2 | Methods of inhibiting αvβ3-mediated binding with αvβ3-specific antibodies | APPLIED MOLECULAR EVOLUTION, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20060204492-A1 | Compositions and methods for producing enhanced antibodies | HUSE WILLIAM D | 2006-09-14 | — | — | US | disclosed |
| US-20040006213-A1 | Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use | IXSYS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030166872-A1 | Anti- alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use | HUSE WILLIAM D (US) | 2003-09-04 | — | — | US | disclosed |
| US-6596850-B1 | Antibody for use in the treatment and prevention of metastasis, osteoporosis, vision defects associated with age, diabetic retinopathy and inflammatory diseases | IXSYS, INCORPORATED | 2003-07-22 | — | — | US | disclosed |
| US-6531580-B1 | Alpha-v/Beta-3 integrins; monoclonal antibody LM609; inhibition of integrin Alpha-v/Beta-3 function; nucleic acids encoding LM609; use therapy of Alpha-v/Beta-3 mediated diseases; cancer, osteoporosis, retinopathy, arthritis | IXSYS, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20030044772-A1 | Methods for identifying ligand specific binding molecules | APPLIED MOLECULAR EVOLUTION [FORMERLY IXSYS] | 2003-03-06 | — | — | US | disclosed |
| US-20030028009-A1 | Compositions and methods for producing enhanced antibodies | IXSYS, INCORPORATED. | 2003-02-06 | — | — | US | disclosed |
| EP-1189946-A1 | ANTI-$g(a) v?$g(b)3? RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE | Applied Molecular Evolution, Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000078815-A1 | ANTI-αvβ3? RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE | APPLIED MOLECULAR EVOLUTION (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-1007967-A2 | METHODS FOR IDENTIFYING LIGAND SPECIFIC BINDING MOLECULES | Ixsys, Incorporated (US) | 2000-06-14 | — | — | EP | disclosed |
| EP-0970217-A2 | ANTI-ALPHA-V BETA-3 RECOMBINANT HUMANIZED ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE | Ixsys, Incorporated (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999006834-A2 | METHODS FOR IDENTIFYING LIGAND SPECIFIC BINDING MOLECULES | IXSYS, INCORPORATED (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1998033919-A2 | ANTI-ALPHA-V BETA-3 RECOMBINANT HUMANIZED ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE | IXSYS, INCORPORATED (US) | 1998-08-06 | — | — | WO | disclosed |